Skip to main content
2024 Guide to Patient Support Services


2024 PSS Guide

IncyteCARES: Connecting to Access, Reimbursement, Education, and Support

Incyte offers IncyteCARES (Connecting to Access, Reimbursement, Education, and Support) to support patients who have been prescribed Jakafi, Pemazyre, or Zynyz (Table).

IncyteCARES Services

IncyteCARES provides several services for patients who are using Jakafi, Pemazyre, or Zynyz, including including information about reimbursement support, financial assistance options, educational support, and referrals to patient advocacy organizations.

Jakafi, Pemazyre, Zynyz Savings Programs

Through these IncyteCARES programs, eligible patients can receive Jakafi, Pemazyre, or Zynyz for as little as $0 per month, subject to monthly and annual limits.

To learn more, call IncyteCARES at 855-452-5234.

IncyteCARES Patient Assistance Program

Patients without prescription drug coverage for Jakafi, Pemazyre, or Zynyz, or those who have been denied claims for treatment with Jakafi, Pemazyre, or Zynyz, may be eligible to receive their medication free of charge through the IncyteCARES Patient Assistance Program.

If underinsured or if uninsured with no coverage, patients may qualify for the Patient Assistance Program if they meet certain household size and annual income criteria or have exhausted their benefits and cannot afford their medication or out-of-pocket expenses. Patients insured under Medicare Part D may qualify by meeting additional criteria and program requirements.

IncyteCARES Temporary Access Program

For patients experiencing a delay in coverage, IncyteCARES may be able to provide a free 30-day supply of the prescribed Incyte medicine to eligible patients.

Nonprofit or Other Support Organizations

Patients who do not qualify for the IncyteCARES programs, including those patients covered by any type of insurance or those without insurance, may be eligible for help with medication costs, treatment-related travel, and other expenses. Referrals to organizations or independent foundations that may offer help can be provided. Eligibility and availability of these assistance programs are determined by the individual organizations.

TABLE Incyte Oncology Drugs

Patient support programs

Jakafi (ruxolitinib) tablets
Treatment of polycythemia vera in adults who have had an inadequate response to, or are intolerant of, hydroxyurea; treatment of intermediate- or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF, and post–essential thrombocythemia MF in adults; treatment of steroid-refractory acute graft-versus-host disease in patients aged ≥12 years; treatment of chronic graft-versus-host disease after failure of 1 or 2 lines of systemic therapy in adult and pediatric patients aged ≥12 years
Patient support programs

Pemazyre (pemigatinib) tablets
Treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or other rearrangement, as detected by an FDA-approved test; treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement
Patient support programs

Zynyz (retifanlimab-dlwr)
Treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma
Patient support programs